[go: up one dir, main page]

WO2001039796A3 - Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases - Google Patents

Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases Download PDF

Info

Publication number
WO2001039796A3
WO2001039796A3 PCT/CA2000/001413 CA0001413W WO0139796A3 WO 2001039796 A3 WO2001039796 A3 WO 2001039796A3 CA 0001413 W CA0001413 W CA 0001413W WO 0139796 A3 WO0139796 A3 WO 0139796A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
prevention
treatment
vaccine
related diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2000/001413
Other languages
French (fr)
Other versions
WO2001039796A2 (en
Inventor
Robert Chalifour
Lise Hebert
Xianqi Kong
Francine Gervais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bellus Health Inc
Original Assignee
Neurochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU18473/01A priority Critical patent/AU784312B2/en
Priority to MXPA02005576A priority patent/MXPA02005576A/en
Priority to JP2001541528A priority patent/JP2004500354A/en
Priority to IL14992400A priority patent/IL149924A0/en
Priority to CA002388559A priority patent/CA2388559A1/en
Priority to BR0016022-9A priority patent/BR0016022A/en
Priority to HK03100407.4A priority patent/HK1049279A1/en
Priority to KR1020027006845A priority patent/KR20020073341A/en
Application filed by Neurochem Inc filed Critical Neurochem Inc
Priority to EP00981111A priority patent/EP1235587A2/en
Publication of WO2001039796A2 publication Critical patent/WO2001039796A2/en
Publication of WO2001039796A3 publication Critical patent/WO2001039796A3/en
Priority to NO20022531A priority patent/NO20022531L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a stereochemically based 'non-self' antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring peptides, proteins or immunogens.
PCT/CA2000/001413 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases Ceased WO2001039796A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
HK03100407.4A HK1049279A1 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases comprising all-d peptides
JP2001541528A JP2004500354A (en) 1999-11-29 2000-11-29 Vaccine for prevention and treatment of Alzheimer's disease and amyloid-related diseases, comprising a whole D-peptide
IL14992400A IL149924A0 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
CA002388559A CA2388559A1 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
BR0016022-9A BR0016022A (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's disease and amyloid-related diseases
AU18473/01A AU784312B2 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
MXPA02005576A MXPA02005576A (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer s and amyloid related diseases.
KR1020027006845A KR20020073341A (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP00981111A EP1235587A2 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases comprising all-d peptides
NO20022531A NO20022531L (en) 1999-11-29 2002-05-28 Vaccine for the prevention and treatment of Alzheimer's and amyloid-related diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16859499P 1999-11-29 1999-11-29
US60/168,594 1999-11-29
US72484200A 2000-11-28 2000-11-28
US09/724,842 2000-11-28

Publications (2)

Publication Number Publication Date
WO2001039796A2 WO2001039796A2 (en) 2001-06-07
WO2001039796A3 true WO2001039796A3 (en) 2001-12-06

Family

ID=26864284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001413 Ceased WO2001039796A2 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

Country Status (13)

Country Link
EP (1) EP1235587A2 (en)
JP (1) JP2004500354A (en)
KR (2) KR20080059676A (en)
CN (1) CN1433321A (en)
AU (1) AU784312B2 (en)
BR (1) BR0016022A (en)
CA (1) CA2388559A1 (en)
HK (1) HK1049279A1 (en)
IL (1) IL149924A0 (en)
MX (1) MXPA02005576A (en)
NO (1) NO20022531L (en)
NZ (1) NZ540564A (en)
WO (1) WO2001039796A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8835654B2 (en) 2004-12-22 2014-09-16 Bhi Limited Partnership Method and compositions for treating amyloid-related diseases
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
KR20080017471A (en) * 2000-02-21 2008-02-26 파멕사 에이/에스 Novel method for down-regulation of amyloid
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
AU2007200047B2 (en) * 2000-07-07 2009-11-26 Bioarctic Neuroscience Ab Prevention and treatment of Alzheimer's disease
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
US7311893B2 (en) 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
PE20020574A1 (en) 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
AR038568A1 (en) * 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003247688A1 (en) 2002-07-03 2004-01-23 Bio Science International, Inc. Peptides comprising aromatic d-amino acids and methods of use
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
JP2007516938A (en) * 2003-06-23 2007-06-28 ニューロケム （インターナショナル） リミテッド Methods and compositions for treating amyloid-related diseases
US8227403B2 (en) * 2003-12-17 2012-07-24 Wyeth Llc A-β immunogenic peptide carrier conjugates and methods of producing same
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
JP2008523815A (en) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド Humanized amyloid beta antibody for use in improving cognition
KR100851035B1 (en) 2005-08-23 2008-08-11 대한민국 - - Pharmaceutical composition and composition for screening therapeutics to preventing and treating of -amyloid accumulation in brain comprising GCP-Glutamate carboxypeptidase- as an active ingredient method for screening using said composition
EP1951750A4 (en) 2005-11-10 2009-12-09 Roskamp Res Llc Modulation of angiogenesis by a-beta peptide fragments
PL1976877T5 (en) 2005-11-30 2017-09-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
BRPI0619747B8 (en) * 2005-12-12 2021-05-25 Ac Immune Sa method of producing a therapeutic vaccine composition, antigenic construct, vaccine composition, uses of an antigenic construct, and, method of preparing and producing a medicament for the treatment of a condition or disease associated with amyloid
ATE517923T1 (en) 2005-12-12 2011-08-15 Hoffmann La Roche ANTIBODIES AGAINST AMYLOID BETA WITH GLYCOSYLATION IN THE VARIABLE REGION
PL2004688T5 (en) 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Improved antibodies to protofibrils and their uses
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TWI608014B (en) * 2006-07-14 2017-12-11 Ａｃ免疫公司 Anti-beta-amyloid antibodies or antigen-binding fragments thereof, the use and method of use thereof
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
DK2074145T5 (en) * 2006-10-02 2017-10-16 Ac Immune Sa HUMANIZED ANTIBODY AGAINST AMYLOID BETA
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2149584B1 (en) 2007-04-20 2017-12-13 The Chemo-Sero-Therapeutic Research Institute Method for enhancing immune response with peptide
JP2010528583A (en) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム Humanized antibody against amyloid β
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
SI2182983T1 (en) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
WO2009143489A2 (en) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2273273A1 (en) * 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
UA121550C2 (en) 2014-07-10 2020-06-25 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
HUE057952T2 (en) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
CN114057884A (en) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 Bispecific anti-human CD20/human transferrin receptor antibody and methods of use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
KR20180094876A (en) 2015-11-09 2018-08-24 더 유니버시티 오브 브리티쉬 콜롬비아 Amyloid beta epitopes and antibodies thereto
KR102786245B1 (en) 2015-11-09 2025-03-26 더 유니버시티 오브 브리티쉬 콜롬비아 Epitopes within the amyloid beta intermediate domain and antibodies structurally selective therefor
CN109476729A (en) 2016-07-18 2019-03-15 英属哥伦比亚大学 Antibodies to amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008868A1 (en) * 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
WO1999058564A1 (en) * 1998-05-08 1999-11-18 Norsk Hydro Asa Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use
WO2000068263A2 (en) * 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008868A1 (en) * 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
WO1999058564A1 (en) * 1998-05-08 1999-11-18 Norsk Hydro Asa Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use
WO2000068263A2 (en) * 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENKIRANE NADIA ET AL: "Antigenicity and immunogenicity of modified synthetic peptides containing D-amino acid residues: Antibodies to a D-enantiomer do recognize the parent L-hexapeptide and reciprocally.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 35, 1993, pages 26279 - 26285, XP002164690, ISSN: 0021-9258 *
VAN REGENMORTEL M H ET AL: "D - peptides as immunogens and diagnostic reagents.", CURRENT OPINION IN BIOTECHNOLOGY, (1998 AUG) 9 (4) 377-82. REF: 37, XP000990989 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8835654B2 (en) 2004-12-22 2014-09-16 Bhi Limited Partnership Method and compositions for treating amyloid-related diseases
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
CA2388559A1 (en) 2001-06-07
CN1433321A (en) 2003-07-30
HK1049279A1 (en) 2003-05-09
JP2004500354A (en) 2004-01-08
IL149924A0 (en) 2002-11-10
NZ540564A (en) 2007-04-27
KR20020073341A (en) 2002-09-23
MXPA02005576A (en) 2002-12-13
AU784312B2 (en) 2006-03-09
EP1235587A2 (en) 2002-09-04
AU1847301A (en) 2001-06-12
WO2001039796A2 (en) 2001-06-07
BR0016022A (en) 2002-08-06
NO20022531L (en) 2002-07-12
KR20080059676A (en) 2008-06-30
NO20022531D0 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
WO2001039796A3 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2002096937A3 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2000072876A3 (en) Prevention and treatment of amyloidogenic disease
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
EP1918300A3 (en) Peptide-based immunization therapy for treatment of atherosclerosis
EP2258383A3 (en) Antigenic peptides derived from telomerase
AU2002223640A1 (en) Fusion proteins as immunization treatments of alzheimer's disease
WO2003020764A3 (en) Modified factor ix
WO2005087261A3 (en) Identification of self and non-self antigens implicated in autoimmune diseases
WO2000078344A8 (en) Prion protein peptides and uses thereof
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
WO2000076540A3 (en) Streptococcus pneumoniae proteins and vaccines
WO2000018351A3 (en) Aglyco products and methods of use
WO2002059143A3 (en) Therapeutic peptides for demyelinating conditions
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
PL371278A1 (en) Modified factor viii
WO2001014395A3 (en) Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
WO2002058725A3 (en) Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine
WO2001058470A3 (en) Methods for enhancing the bioavailability of a drug
WO2003055440A3 (en) Compositions and methods for the treatement of immune related diseases
WO2002070004A3 (en) Papillomavirus vaccines
MXPA04004970A (en) T-cell epitodes in carboxypeptidase g2.
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002074332A3 (en) Method to enhance the immunogenicity of an antigen
WO2003074003A3 (en) Immunogens for treatment of neoplastic and infectious disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2002 200201317

Country of ref document: RO

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2388559

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 18473/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 519117

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2001 541528

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 149924

Country of ref document: IL

Ref document number: 1020027006845

Country of ref document: KR

Ref document number: 008164142

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/005576

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000981111

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000981111

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027006845

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642